Clinicopathological findings following intraventricular glial‐derived neurotrophic factor treatment in a patient with Parkinson's disease
暂无分享,去创建一个
Timothy Sendera | Richard Penn | R. Penn | C. Goetz | E. Cochran | E. Mufson | J. Kordower | T. Sendera | E. Chen | S. Palfi | Elliott J. Mufson | Christopher G. Goetz | Jeffrey H. Kordower | Stephane Palfi | Er‐Yun Chen | Shuang Y. Ma | Elizabeth J. Cochran | Cynthia D. Comella | C. Comella | Shuang Y. Ma
[1] J. Qian,et al. Behavioral and Cellular Protection of Rat Dopaminergic Neurons by an Adenoviral Vector Encoding Glial Cell Line-Derived Neurotrophic Factor , 1998, Experimental Neurology.
[2] M. D. Lindner,et al. Alleviation of behavioral deficits in aged rodents following implantation of encapsulated GDNF-producing fibroblasts , 1996, Brain Research.
[3] A. Björklund,et al. Studies on Neuroprotective and Regenerative Effects of GDNF in a Partial Lesion Model of Parkinson's Disease , 1997, Neurobiology of Disease.
[4] B. Davidson,et al. Dopaminergic Neurons Protected from Degeneration by GDNF Gene Therapy , 1997, Science.
[5] D. Hilt,et al. Pharmacological Activities of Glial Cell Line-Derived Neurotrophic Factor (GDNF): Preclinical Development and Application to the Treatment of Parkinson's Disease , 1997, Experimental Neurology.
[6] S. Hersch,et al. The dopamine transporter: immunochemical characterization and localization in brain , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[7] E. Mufson,et al. Functional fetal nigral grafts in a patient with Parkinson's disease: Chemoanatomic, ultrastructural, and metabolic studies , 1996, The Journal of comparative neurology.
[8] J. Mallet,et al. Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[9] P R Sanberg,et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. , 1995, The New England journal of medicine.
[10] Shelley R. Winn,et al. Implantation of encapsulated catecholamine and GDNF-producing cells in rats with unilateral dopamine depletions and parkinsonian symptoms , 1995, Experimental Neurology.
[11] K. Yagi,et al. Adenovirus-mediated transduction with human glial cell line-derived neurotrophic factor gene prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopamine depletion in striatum of mouse brain. , 1997, Biochemical and biophysical research communications.
[12] S. Leff,et al. Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[13] K. Jellinger,et al. Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway. , 1991, Molecular and chemical neuropathology.
[14] C. Spenger,et al. Implants of Polymer-Encapsulated Genetically Modified Cells Releasing Glial Cell Line-Derived Neurotrophic Factor Improve Survival, Growth, and Function of Fetal Dopaminergic Grafts , 1998, Experimental Neurology.
[15] S. Kish,et al. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. , 1988, The New England journal of medicine.